Mortality at maximal · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Mortality at maximal · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes mortality at maximal compared with no intervention (very low certainty).
1 finding from 1 review
Early mortality (mortality up to 90 days) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes early mortality (mortality up to 90 days) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (proportion) · participants with severe alcoholic hepatitis
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Serious adverse events (number) · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)
It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with severe alcoholic hepatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (number) · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · participants with alcoholic hepatitis (all severity)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients with resolution or improved symptoms at days 3 to 7 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
3 findings from 1 review
RR 1.33 [1.09, 1.62]
5 studies · 1043 participants
Moderate
RR 1.4 [1.08, 1.81]
4 studies · 869 participants
Low
RR 1.12 [0.87, 1.44]
1 study · 174 participants
Moderate
Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
2 findings from 1 review
Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
1 finding from 1 review
Adverse events · patients with acute sinusitis
1 finding from 1 review
Complete resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher complete resolution of phimosis compared with placebo or no treatment (low certainty).
2 findings from 1 review
Partial resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher partial resolution of phimosis compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in retractability score · boys up to 18 years old with phimosis
It is very uncertain whether topical corticosteroids changes change in retractability score compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse effects (any) · boys up to 18 years old with phimosis
Topical corticosteroids showed no clear difference in adverse effects (any) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes combined outcome of mortality or BPD at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review
Mortality at 36 weeks' PMA · preterm infants
It is very uncertain whether inhaled corticosteroids changes mortality at 36 weeks' PMA compared with placebo (very low certainty).
1 finding from 1 review